Skip to main content

Advertisement

Table 2 Relationship between beta blocker use and hypoglycemia

From: Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients

 Overall No basal insulin Basal insulin 
OR 95% CI p-value p-value interaction^OR 95% CI p-value OR 95% CI p-value 
Odds ratio for glucose < 3.9 mmol/L (70 mg/dL) within 24 h 
 Unadjusted model
  Carvedilol vs. none3.012.48–3.71< 0.00012.561.95–3.37< 0.00010.910.65–1.270.58
  SBB vs. none4.023.30–4.89< 0.00014.963.89–6.33< 0.00010.620.44–0.880.008
  SBB vs carvedilol1.32 1.03–1.70 0.031.94 1.39–2.70 0.00010.68 0.46–1.02 0.06 
 Adjusted model
  Carvedilol vs. none 1.45 1.05–2.01 0.0245< 0.00012.15 1.38–3.37 0.00071.18 0.74–1.90 0.49
  SBB vs. none 1.78 1.31–2.40 0.00024.292.96–6.20 < 0.00010.820.51–1.32 0.42
  SBB vs. carvedilol1.22 0.87–1.72 0.251.991.28–3.09 0.00230.70 0.41–1.18 0.18
Odds ratio for glucose < 3.9 mmol/L (70 mg/dL) overall 
 Unadjusted model 
  Carvedilol vs. none 4.72 4.10–5.42 < 0.00013.39 2.82–4.09 < 0.00011.05 0.72–1.51 0.81
  SBB vs. none 7.49 6.48–8.66 < 0.00016.305.25–7.56 < 0.00010.910.64–1.29 0.58
  SBB vs. carvedilol 1.59 1.32–1.90 < 0.00011.861.46–2.35 < 0.00010.870.58–1.30 0.48
 Adjusted model 
  Carvedilol vs. none 2.56 1.94–3.37 < 0.0001<0.00016.30 4.59–8.65 < 0.00011.03 0.65–1.63 0.91
  SBB vs. none 2.61 2.05–3.33 < 0.00018.696.57–11.5 < 0.00010.860.56–1.31 0.48
  SBB vs. carvedilol 1.02 0.77–1.35 0.891.381.02–1.86 0.030.840.52–1.36 0.47
Odds ratio for glucose < 2.2 mmol/L (40 mg/dL) overall 
 Unadjusted model 
  Carvedilol vs. none 3.69 2.62–5.18 < 0.00012.63 1.50–4.60 0.0007 1.04 0.65–1.64 0.88
  SBB vs. none 3.90 2.74–5.54 < 0.00016.12 3.91–9.58 < 0.00010.450.25–0.80 0.007
  SBB vs. carvedilol 1.06 0.69–1.61 0.80 2.33 1.23–4.43 0.00980.430.23–0.81 0.009
 Adjusted model 
  Carvedilol vs. none 1.68 1.03–2.74 0.04 < 0.00013.21 1.49–6.91 0.0029 1.11 0.58–2.10 0.76
  SBB vs. none1.70 1.06–2.75 0.036.11 3.37–11.1 < 0.00010.560.26–1.20 0.13
  SBB vs. carvedilol1.10 0.59–1.75 0.971.90 0.90–4.02 0.090.500.22–1.14 0.10
  1. All adjusted models adjusted for age, gender, race, body mass index*, surgery service, admission glucose*, admission creatinine*, basal insulin use, heart failure, hospital length of stay, cardiovascular service, statin, aspirin, ACE/ARB, ^basal insulin by BB type interaction. * log transformed values
  2. BB beta blocker, SBB selective beta blocker